Valion Bio Inc Dossier - Source-backed chat

Valion Bio Inc

VBIONASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.80Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $2.5M

Shares Outstanding 887.6K diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Valion Bio Inc. (formerly Tivic Health Systems, Inc.) has completed a dramatic strategic pivot from a consumer medical device business to a late-stage biopharmaceutical platform. The company's investment thesis is anchored by Entolimod, a TLR5 agonist with over $140 million in historical development funding, being advanced under the FDA's Animal Rule for Acute Radiation Syndrome (ARS). While the potential for a non-dilutive, nine-figure government procurement contract or international stockpiling (e.g., Ukraine, which is formally reviewing the drug) provides massive asymmetric upside, the company is currently constrained by severe financial distress. With a market capitalization of approximately $1 million and a rapid cash burn rate, Valion Bio remains highly dependent on securing immediate government funding or dilutive capital raises. Consequently, a 'Hold' recommendation is warranted until clear regulatory approvals or procurement contracts materialize.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.1020%

The company fails to secure government procurement contracts or non-dilutive funding from BARDA or NIAID. Ukraine's Ministry of Health rejects or delays the Entolimod dossier. Severe cash depletion forces the company into highly dilutive financing rounds or restructuring, causing the stock to trade near its historical lows with heightened going-concern risk.

Base CaseCentral scenario

$0.5060%

Valion Bio continues to advance its regulatory discussions with BARDA, NIAID, and Ukraine's Ministry of Health. The Sheba Medical Center trial begins enrollment in late 2026 with positive interim data in early 2027. However, the company is forced to execute additional small-scale private placements or dilutive equity offerings to sustain operations, capping near-term share price appreciation despite operational progress.

Bull CaseUpside scenario

$2.5020%

The company successfully secures a multi-million dollar procurement contract with BARDA or allied nations for the Strategic National Stockpile, validating the Animal Rule pathway. Simultaneously, the Sheba Medical Center clinical trial demonstrates Entolimod's efficacy in reducing radiation-induced neutropenia, opening up the multi-billion-dollar oncology supportive care market. Velocity Bioworks scales up and signs its first major third-party CDMO contracts, establishing a steady stream of commercial revenue.

Scenarios reflect our research view at the research date.

Key Investment Merits

De-risked regulatory pathway under the FDA Animal Rule for Acute Radiation Syndrome, utilizing over $140 million in prior institutional and government funding.
Dual-utility platform with parallel expansion into the $22 billion oncology supportive care market (neutropenia) via physician-sponsored trials.
Vertically integrated domestic biomanufacturing capability through wholly owned subsidiary Velocity Bioworks, securing the supply chain and offering third-party CDMO revenue potential.

Key Investment Risks

Extreme financial distress and high cash burn rate, with a market capitalization of around $1 million, creating severe dilution and going-concern risks.
High concentration of near-term value on binary government procurement decisions and regulatory approvals which have no guaranteed execution timeline.
Velocity Bioworks has yet to establish material third-party commercial CDMO revenues to offset internal drug development costs.

Thesis Invalidation Triggers

Definitive rejection or termination of engagement by BARDA or other key U.S. defense agencies regarding Entolimod procurement.
Failure to obtain IRB approval or initiate patient enrollment for the Sheba Medical Center clinical trial by Q1 2027.
Inability to secure near-term capital, leading to insolvency or delisting from the Nasdaq Capital Market.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.